-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 24, Haisco submitted an application for the listing of 2.
From: CDE
HSK3486 (i.
On December 14, 2020, cyclopofol was approved for marketing for the first time for gastrointestinal endoscopic diagnosis and treatment of sedation and/or anesthesia; in February 2021, a new indication was approved for general anesthesia induction; this year In February, June and November, 3 new indications were successively declared
According to the Insight database, Haisco has currently initiated 6 phase 3 clinical trials for cycloporol, 5 of which have been completed, which most likely corresponds to the 5 indications declared by it
Phase III clinical registration of cyclopofol
From: Insight database (http://db.
The benchmark product of HSK3486, propofol, is the flagship product in the field of intravenous anesthesia and sedation
However, 10 propofol companies have been approved and included in the fourth batch of centralized procurement.
As a me-better product of propofol, cyclopofol is also one of the important players in this year's medical insurance negotiations